{"id":71446,"date":"2026-05-20T11:50:00","date_gmt":"2026-05-20T11:50:00","guid":{"rendered":"https:\/\/medsbase.com\/aod-9604\/"},"modified":"2026-10-15T10:33:56","modified_gmt":"2026-10-15T10:33:56","slug":"aod-9604","status":"publish","type":"product","link":"https:\/\/medsbase.com\/ja\/product\/aod-9604\/","title":{"rendered":"AOD-9604\uff08\u6297\u80a5\u6e80\u85ac9604 \/ Tyr-hGH 177-191\uff09"},"content":{"rendered":"<p><!-- medsbase-tldr-answer --><\/p>\n<div style=\"background: #fff8e1; border-left: 4px solid #f5a623; padding: 18px 22px; margin: 18px 0; border-radius: 4px;\">\n<h3 style=\"margin: 0 0 8px 0; font-size: 16px; color: #1a4a6b;\">\u30af\u30a4\u30c3\u30af\u30a2\u30f3\u30b5\u30fc \u2014 AOD-9604\u3068\u306f\uff1f<\/h3>\n<p style=\"margin: 0;\"><strong>AOD-9604<\/strong> \uff08\u300c\u6297\u80a5\u6e80\u85ac9604\u300d\u3001CAS 221231-10-3\uff09\u306f\u3001\u5408\u621016\u30a2\u30df\u30ce\u9178\u30da\u30d7\u30c1\u30c9\u3067\u3001\u958b\u767a\u5143\u306f <strong>Metabolic Pharmaceuticals Ltd<\/strong> \uff08\u30aa\u30fc\u30b9\u30c8\u30e9\u30ea\u30a2\uff09\u306b\u3088\u3063\u30661990\u5e74\u4ee3\u5f8c\u534a\u306b\u3001\u30d2\u30c8\u6210\u9577\u30db\u30eb\u30e2\u30f3\u306eC\u672b\u7aef\u8102\u80aa\u5206\u89e3\u30d5\u30e9\u30b0\u30e1\u30f3\u30c8\u306e\u5b89\u5b9a\u5316\u30a2\u30ca\u30ed\u30b0\u3068\u3057\u3066\u958b\u767a\u3055\u308c\u307e\u3057\u305f\u3002\u914d\u5217\uff1aTyr-Leu-Arg-Ile-Val-Gln-Cys-Arg-Ser-Val-Glu-Gly-Ser-Cys-Gly-Phe\uff0816\u30a2\u30df\u30ce\u9178\u3001N\u672b\u7aef\u30c1\u30ed\u30b7\u30f3\u4f38\u9577\u306b\u3088\u308a\u89aahGH 177\u2013191\u30d5\u30e9\u30b0\u30e1\u30f3\u30c8\u3092\u5b89\u5b9a\u5316\u3057\u3001Cys7\u2013Cys14\u5206\u5b50\u5185\u30b8\u30b9\u30eb\u30d5\u30a3\u30c9\u7d50\u5408\u3092\u6301\u3064\uff09\u3002\u5206\u5b50\u5f0f C<sub>78<\/sub>H<sub>123<\/sub>N<sub>23<\/sub>O<sub>23<\/sub>S<sub>2<\/sub>, MW 1815.1 Da. In published in-vitro and rodent studies AOD-9604 retains the <strong>\u8102\u80aa\u5206\u89e3\u304a\u3088\u3073\u8102\u80aa\u84c4\u7a4d\u6291\u5236\u6d3b\u6027<\/strong> \u89aahGH\u5206\u5b50\u306e\u3082\u306e\u3092\u4fdd\u6301\u3057\u307e\u3059\u304c\u3001 <em>\u3057\u307e\u305b\u3093<\/em> bind the GH receptor \u2014 so it does not induce IGF-1, does not activate growth-axis JAK2\/STAT5 signalling, and does not produce the growth-promoting effects of full-length HGH. Failed Phase IIb obesity trial (2007); now used as a pharmaceutical-grade peptide. <em>For clinical studies use only.<\/em><\/p>\n<\/div>\n<div class=\"medsbase-trust-strip\" style=\"background: #f4f8fb; border: 1px solid #d8e3eb; padding: 12px 16px; margin: 16px 0; border-radius: 4px; font-size: 14px;\"><strong>MedsBase\u3067\u5f97\u3089\u308c\u308b\u3082\u306e\uff1a<\/strong> Pharmaceutical-grade lyophilized peptides &middot; HPLC &ge;99% purity (COA on request) &middot; Discreet protective packaging &middot; Worldwide peptide courier &middot; 1,400+ verified <a href=\"https:\/\/medsbase.com\/ja\/reviews\/\">\u30ab\u30b9\u30bf\u30de\u30fc\u30ec\u30d3\u30e5\u30fc<\/a><\/div>\n<p class=\"medsbase-reship-line\" style=\"font-size: 14px; color: #444; margin: 8px 0 18px;\">\ud83d\udce6 \u3059\u3079\u3066\u306e\u3054\u6ce8\u6587\u306f\u3001\u5f53\u5e97\u306e <a href=\"https:\/\/medsbase.com\/ja\/medsbase-re-shipment-assurance-policy\/\"><strong>\u518d\u767a\u9001\u4fdd\u8a3c\u30dd\u30ea\u30b7\u30fc<\/strong><\/a> \u2014 \u4e07\u304c\u4e00\u300120\u55b6\u696d\u65e5\u4ee5\u5185\u306b\u5546\u54c1\u304c\u5c4a\u304b\u306a\u3044\u5834\u5408\u306f\u3001\u518d\u767a\u9001\u3044\u305f\u3057\u307e\u3059\u3002<\/p>\n<table class=\"medsbase-spec-table\" style=\"width: 100%; border-collapse: collapse; margin: 18px 0; font-size: 14px;\">\n<thead>\n<tr style=\"background: #2c7cb0; color: #fff;\">\n<th style=\"padding: 8px 12px; text-align: left; width: 30%;\">\u4ed5\u69d8<\/th>\n<th style=\"padding: 8px 12px; text-align: left;\">\u8a73\u7d30<\/th>\n<\/tr>\n<\/thead>\n<tbody>\n<tr style=\"background: #f9f9f9;\">\n<td style=\"padding: 8px 12px; border-bottom: 1px solid #e0e0e0; width: 30%;\"><strong>\u5316\u5408\u7269\u30af\u30e9\u30b9<\/strong><\/td>\n<td style=\"padding: 8px 12px; border-bottom: 1px solid #e0e0e0;\">Synthetic 16-amino-acid peptide; stabilised C-terminal hGH-fragment analogue; lipolytic \/ anti-lipogenic peptide (decoupled from GH-receptor binding)<\/td>\n<\/tr>\n<tr style=\"background: #fff;\">\n<td style=\"padding: 8px 12px; border-bottom: 1px solid #e0e0e0; width: 30%;\"><strong>\u5316\u5b66\u540d<\/strong><\/td>\n<td style=\"padding: 8px 12px; border-bottom: 1px solid #e0e0e0;\">AOD-9604\uff08\u300c\u6297\u80a5\u6e80\u85ac9604\u300d\u3001\u5225\u540d\uff1aTyr-hGH 177-191\uff1bH-Tyr-(177-191 hGH fragment)-OH\uff09<\/td>\n<\/tr>\n<tr style=\"background: #f9f9f9;\">\n<td style=\"padding: 8px 12px; border-bottom: 1px solid #e0e0e0; width: 30%;\"><strong>CAS\u756a\u53f7<\/strong><\/td>\n<td style=\"padding: 8px 12px; border-bottom: 1px solid #e0e0e0;\">221231-10-3\uff08Sigma-Aldrich\u3001MedKoo\u3001ChemicalBook\u306e\u6a19\u6e96CAS\u756a\u53f7\uff09<\/td>\n<\/tr>\n<tr style=\"background: #fff;\">\n<td style=\"padding: 8px 12px; border-bottom: 1px solid #e0e0e0; width: 30%;\"><strong>\u5206\u5b50\u5f0f<\/strong><\/td>\n<td style=\"padding: 8px 12px; border-bottom: 1px solid #e0e0e0;\">C<sub>78<\/sub>H<sub>123<\/sub>N<sub>23<\/sub>O<sub>23<\/sub>S<sub>2<\/sub><\/td>\n<\/tr>\n<tr style=\"background: #f9f9f9;\">\n<td style=\"padding: 8px 12px; border-bottom: 1px solid #e0e0e0; width: 30%;\"><strong>\u5206\u5b50\u91cf<\/strong><\/td>\n<td style=\"padding: 8px 12px; border-bottom: 1px solid #e0e0e0;\">1815.1 g\/mol<\/td>\n<\/tr>\n<tr style=\"background: #fff;\">\n<td style=\"padding: 8px 12px; border-bottom: 1px solid #e0e0e0; width: 30%;\"><strong>\u914d\u5217<\/strong><\/td>\n<td style=\"padding: 8px 12px; border-bottom: 1px solid #e0e0e0;\">Tyr-Leu-Arg-Ile-Val-Gln-Cys-Arg-Ser-Val-Glu-Gly-Ser-Cys-Gly-Phe\uff08\u4e00\u6587\u5b57\u8868\u8a18\uff1aYLRIVQCRSVEGSCGF\uff1b16\u30a2\u30df\u30ce\u9178\uff09\u3002Cys7\u2013Cys14\u306e\u5206\u5b50\u5185\u30b8\u30b9\u30eb\u30d5\u30a3\u30c9\u67b6\u6a4b\u304c\u74b0\u72b6\u69cb\u9020\u3092\u5f62\u6210\u3057\u3001\u89aahGH\u306e182\uff5e189\u9818\u57df\u306e\u30b8\u30b9\u30eb\u30d5\u30a3\u30c9\u69cb\u9020\u3092\u6a21\u5023\u3057\u307e\u3059\u3002N\u672b\u7aef\u306e\u30c1\u30ed\u30b7\u30f3\u306f\u5408\u6210\u4ed8\u52a0\u7269\uff08\u5929\u7136hGH 177-191\u306b\u306f\u5b58\u5728\u3057\u306a\u3044\uff09\u3067\u3042\u308a\u3001\u30a2\u30df\u30ce\u672b\u7aef\u306e\u30bf\u30f3\u30d1\u30af\u8cea\u5206\u89e3\u304b\u3089\u30d5\u30e9\u30b0\u30e1\u30f3\u30c8\u3092\u5b89\u5b9a\u5316\u3057\u307e\u3059\u3002<\/td>\n<\/tr>\n<tr style=\"background: #f9f9f9;\">\n<td style=\"padding: 8px 12px; border-bottom: 1px solid #e0e0e0; width: 30%;\"><strong>\u4f5c\u7528\u6a5f\u5e8f<\/strong><\/td>\n<td style=\"padding: 8px 12px; border-bottom: 1px solid #e0e0e0;\"><strong>\u6a5f\u69cb\u7684\u306b\u72ec\u7acb\u3057\u305f\u8102\u80aa\u5206\u89e3<\/strong>. \u3002AOD-9604\u306fGH\u53d7\u5bb9\u4f53\uff08GHR\uff09\u306b\u7d50\u5408\u3057\u307e\u305b\u3093 \u2014 \u5929\u7136hGH\u306eGHR\u7d50\u5408\u9762\u306fN\u672b\u7aef\u90e8\u5206\uff08\u6b8b\u57fa1\uff5e120\u9818\u57df\uff09\u306b\u3042\u308a\u3001176-191\u30d5\u30e9\u30b0\u30e1\u30f3\u30c8\u306b\u306f\u5b58\u5728\u3057\u307e\u305b\u3093\u3002\u8102\u80aa\u5206\u89e3\/\u8102\u80aa\u84c4\u7a4d\u6291\u5236\u6d3b\u6027\u306f\u3001\u03b23\u30a2\u30c9\u30ec\u30ca\u30ea\u30f3\u53d7\u5bb9\u4f53\u30b7\u30b0\u30ca\u30eb\u4f1d\u9054\u304a\u3088\u3073cAMP-PKA\u3092\u4ecb\u3057\u305f\u8102\u80aa\u7d30\u80de\u306e\u30db\u30eb\u30e2\u30f3\u611f\u53d7\u6027\u30ea\u30d1\u30fc\u30bc\uff08HSL\uff09\u306e\u76f4\u63a5\u6d3b\u6027\u5316\u306b\u3088\u3063\u3066\u5a92\u4ecb\u3055\u308c\u308b\u3068\u8003\u3048\u3089\u308c\u3066\u3044\u307e\u3059\u3002\u516c\u8868\u6587\u732e\u3067\u306f\u30e1\u30ab\u30cb\u30ba\u30e0\u306f\u5b8c\u5168\u306b\u306f\u89e3\u660e\u3055\u308c\u3066\u304a\u3089\u305a\u3001C\u672b\u7aef\u8102\u80aa\u5206\u89e3\u30d5\u30e9\u30b0\u30e1\u30f3\u30c8\u306e\u53d7\u5bb9\u4f53\u306f\u5358\u4e00\u3067\u78ba\u8a8d\u3055\u308c\u3066\u3044\u307e\u305b\u3093\u3002<\/td>\n<\/tr>\n<tr style=\"background: #fff;\">\n<td style=\"padding: 8px 12px; border-bottom: 1px solid #e0e0e0; width: 30%;\"><strong>\u8840\u6f3f\u4e2d\u534a\u6e1b\u671f<\/strong><\/td>\n<td style=\"padding: 8px 12px; border-bottom: 1px solid #e0e0e0;\">~4\u5206\uff08\u975e\u5e38\u306b\u77ed\u3044 \u2014 \u5b89\u5b9a\u5316Tyr\u306b\u3082\u304b\u304b\u308f\u3089\u305aN\u672b\u7aef\u306e\u30bf\u30f3\u30d1\u30af\u8cea\u5206\u89e3\u306b\u3088\u308b\u5207\u65ad\u304c\u539f\u56e0\uff09\u3002\u3053\u306e\u77ed\u3044\u534a\u6e1b\u671f\u304c\u3001\u7b2cIIb\u76f8\u80a5\u6e80\u8a66\u9a13\uff082007\u5e74\uff09\u304c\u4f53\u91cd\u6e1b\u5c11\u30a8\u30f3\u30c9\u30dd\u30a4\u30f3\u30c8\u3092\u9054\u6210\u3067\u304d\u306a\u304b\u3063\u305f\u7406\u7531\u306e\u6709\u529b\u306a\u4eee\u8aac\u306e\u4e00\u3064\u3067\u3059 \u2014 \u30d5\u30e9\u30b0\u30e1\u30f3\u30c8\u306f\u6a19\u7684\u7d44\u7e54\u3067\u5341\u5206\u306a\u53d7\u5bb9\u4f53\u66dd\u9732\u304c\u84c4\u7a4d\u3059\u308b\u524d\u306b\u5206\u89e3\u3055\u308c\u307e\u3059\u3002<\/td>\n<\/tr>\n<tr style=\"background: #f9f9f9;\">\n<td style=\"padding: 8px 12px; border-bottom: 1px solid #e0e0e0; width: 30%;\"><strong>\u5f62\u614b<\/strong><\/td>\n<td style=\"padding: 8px 12px; border-bottom: 1px solid #e0e0e0;\">Lyophilized white-to-off-white amorphous powder; single-use vials<\/td>\n<\/tr>\n<tr style=\"background: #fff;\">\n<td style=\"padding: 8px 12px; border-bottom: 1px solid #e0e0e0; width: 30%;\"><strong>\u7d14\u5ea6<\/strong><\/td>\n<td style=\"padding: 8px 12px; border-bottom: 1px solid #e0e0e0;\">\u226599%\uff08HPLC\u691c\u8a3c\u6e08\u307f\uff09\uff1bMALDI-TOF\u8cea\u91cf\u5206\u6790\u306b\u3088\u308a1815.1 Da\u3092\u78ba\u8a8d\u3002\u5206\u6790\u8a3c\u660e\u66f8\uff08COA\uff09\u306f\u3054\u8981\u671b\u306b\u5fdc\u3058\u3066\u5165\u624b\u53ef\u80fd\u3067\u3059\u3002<\/td>\n<\/tr>\n<tr style=\"background: #f9f9f9;\">\n<td style=\"padding: 8px 12px; border-bottom: 1px solid #e0e0e0; width: 30%;\"><strong>\u6eb6\u89e3\u6027<\/strong><\/td>\n<td style=\"padding: 8px 12px; border-bottom: 1px solid #e0e0e0;\">\u9759\u83cc\u6c34\u3001\u6ec5\u83cc\u6c34\u3001PBS\u3001\u304a\u3088\u30730.1%\u9162\u9178\u306b\u22655 mg\/mL\u3067\u53ef\u6eb6\uff1bin vitro\u30b9\u30c8\u30c3\u30af\u8abf\u88fd\u306e\u305f\u3081DMSO\u306b\u226550 mg\/mL\u3067\u5bb9\u6613\u306b\u6eb6\u89e3\u3057\u307e\u3059\u3002Cys7\u2013Cys14\u30b8\u30b9\u30eb\u30d5\u30a3\u30c9\u67b6\u6a4b\u306f\u30da\u30d7\u30c1\u30c9\u306e\u7acb\u4f53\u69cb\u9020\u3092\u5236\u7d04\u3057\u307e\u3059\u304c\u3001\u6c34\u6eb6\u6027\u3092\u59a8\u3052\u307e\u305b\u3093\u3002<\/td>\n<\/tr>\n<tr style=\"background: #fff;\">\n<td style=\"padding: 8px 12px; border-bottom: 1px solid #e0e0e0; width: 30%;\"><strong>\u4fdd\u7ba1\u65b9\u6cd5<\/strong><\/td>\n<td style=\"padding: 8px 12px; border-bottom: 1px solid #e0e0e0;\">\u51cd\u7d50\u4e7e\u71e5\u54c1\uff1a\u77ed\u671f\u4f7f\u7528\u306e\u672a\u958b\u5c01\u30b9\u30c8\u30c3\u30af\u306f2\uff5e8 \u00b0C\u3001\u9577\u671f\u4fdd\u5b58\u306f\u221220 \u00b0C\uff08\u221220 \u00b0C\u306736\u304b\u6708\u4ee5\u4e0a\u5b89\u5b9a\u30012\uff5e8 \u00b0C\u306718\u304b\u6708\u4ee5\u4e0a\u5b89\u5b9a\uff09\u3002\u518d\u6eb6\u89e3\u5f8c\u306e\u6c34\u6eb6\u6db2\uff1a2\uff5e8 \u00b0C\u3067\u7d0430\u65e5\u4ee5\u5185\u306b\u4f7f\u7528\u3002\u906e\u5149\u4fdd\u5b58\u3002\u518d\u6eb6\u89e3\u6db2\u306e\u51cd\u7d50\u878d\u89e3\u3092\u7e70\u308a\u8fd4\u3055\u306a\u3044\u3053\u3068\u3002\u30b8\u30b9\u30eb\u30d5\u30a3\u30c9\u7d50\u5408\u306f1\u56de\u306e\u51cd\u7d50\u878d\u89e3\u306b\u306f\u5b89\u5b9a\u3067\u3059\u304c\u3001\u7e70\u308a\u8fd4\u3059\u3068\u904a\u96e2\u30c1\u30aa\u30fc\u30eb\u306e\u30b9\u30af\u30e9\u30f3\u30d6\u30ea\u30f3\u30b0\u3084\u90e8\u5206\u7684\u306a\u51dd\u96c6\u304c\u751f\u3058\u308b\u30ea\u30b9\u30af\u304c\u3042\u308a\u307e\u3059\u3002<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n<p><!-- \/medsbase-tldr-answer --><\/p>\n<h2>AOD-9604\u3068\u306f\uff1f<\/h2>\n<p><strong>AOD-9604<\/strong> \uff08\u300cAnti-Obesity Drug 9604\u300d\u3001CAS 221231-10-3\uff09\u306f\u3001 <strong>Metabolic Pharmaceuticals Ltd<\/strong> \u304c\u30aa\u30fc\u30b9\u30c8\u30e9\u30ea\u30a2\u30fb\u30e1\u30eb\u30dc\u30eb\u30f3\u306e\u30e2\u30ca\u30b7\u30e5\u5927\u5b66\u30671990\u5e74\u4ee3\u5f8c\u534a\u3088\u308a\u958b\u767a\u3092\u958b\u59cb\u3057\u305f\u300116\u30a2\u30df\u30ce\u9178\u304b\u3089\u306a\u308b\u5408\u6210\u30da\u30d7\u30c1\u30c9\u3067\u3059\u3002\u5929\u7136\u30d2\u30c8\u6210\u9577\u30db\u30eb\u30e2\u30f3\uff08hGH\uff09\u306eC\u672b\u7aef\u8102\u80aa\u5206\u89e3\u65ad\u7247\uff08\u6b8b\u57fa177\u2013191\uff09\u306b\u5b89\u5b9a\u6027\u3092\u9ad8\u3081\u305f\u30a2\u30ca\u30ed\u30b0\u3067\u3042\u308a\u3001\u30a2\u30df\u30ce\u672b\u7aef\u306e\u5206\u89e3\u3092\u9045\u3089\u305b\u308b\u305f\u3081\u306bN\u672b\u7aef\u306b\u30c1\u30ed\u30b7\u30f3\u304c\u4ed8\u52a0\u3055\u308c\u3066\u3044\u307e\u3059\u3002\u914d\u5217\uff1aTyr-Leu-Arg-Ile-Val-Gln-Cys-Arg-Ser-Val-Glu-Gly-Ser-Cys-Gly-Phe\uff08YLRIVQCRSVEGSCGF\uff09\u3002\u89aahGH\u306eCys182\u2013Cys189\u5206\u5b50\u5185\u30b8\u30b9\u30eb\u30d5\u30a3\u30c9\u7d50\u5408\u304c\u3001\u65ad\u7247\u306e\u756a\u53f7\u4ed8\u3051\u3067\u306fCys7\u2013Cys14\u3068\u3057\u3066\u4fdd\u6301\u3055\u308c\u3066\u3044\u307e\u3059\u3002\u5206\u5b50\u91cf1815.1 g\/mol\u3001\u5b9f\u9a13\u5f0fC<sub>78<\/sub>H<sub>123<\/sub>N<sub>23<\/sub>O<sub>23<\/sub>S<sub>2<\/sub>. The pharmacological logic behind AOD-9604 is one of the cleanest examples of structure-function dissection in HGH peptide studies. Native full-length human growth hormone (191 amino acids) has at least two distinct biological activities: <strong>\u6210\u9577\u4fc3\u9032\uff0f\u540c\u5316\u4f5c\u7528<\/strong> \uff08GH\u53d7\u5bb9\u4f53\u3001JAK2\/STAT5\u30b7\u30b0\u30ca\u30eb\u4f1d\u9054\u3001\u304a\u3088\u3073\u4e0b\u6d41\u306eIGF-1\u7523\u751f\u3092\u4ecb\u3059\u308b\uff09\u3068\u3001 <strong>\u8102\u80aa\u5206\u89e3\uff0f\u8102\u80aa\u751f\u6210\u6291\u5236\u4f5c\u7528<\/strong> (mediated through a separate, incompletely-characterised mechanism that does not require GH-receptor engagement). The Monash group&#8217;s hypothesis was that the lipolytic activity is encoded in the C-terminal region of the molecule \u2014 and that a synthetic peptide encompassing just that region might retain the fat-mobilising activity while losing the growth-axis-engaging activity. This proved correct in published in-vitro and rodent studies: the 176\u2013191 fragment retains lipolytic and anti-lipogenic activity in adipocyte culture and DIO mouse models, but does not bind GHR, does not activate JAK2\/STAT5, and does not induce IGF-1. AOD-9604 progressed through multiple Phase I and Phase II clinical trials in the early-to-mid 2000s, culminating in a 28-week Phase IIb obesity trial (~500 patients) completed in 2007 by Metabolic Pharmaceuticals. The trial did not achieve its primary weight-loss endpoint, and the obesity-pharmacology development programme was discontinued. AOD-9604 subsequently entered the studies-peptide and unregulated-supplement markets, where it has remained one of the most-cited &#8220;fat-loss peptides&#8221; in non-clinical literature. The compound retains studies utility as the canonical pharmacological tool for studying GHR-decoupled lipolysis, the C-terminal hGH fragment biology, and the structure-function basis of HGH&#8217;s multiple activities. A note on nomenclature: AOD-9604 and &#8220;<a href=\"https:\/\/medsbase.com\/ja\/hgh-fragment-176-191\/\">HGH\u30d5\u30e9\u30b0\u30e1\u30f3\u30c8176-191<\/a>&#8221; are often used interchangeably in the supplier and studies-peptide marketplace. Strictly, AOD-9604 (CAS 221231-10-3) is the Metabolic-Pharmaceuticals-developed analogue with the N-terminal Tyr stabilisation. &#8220;HGH Fragment 176-191&#8221; (CAS 66004-57-7 per some references) is the older, un-stabilised hGH 177\u2013191 fragment that AOD-9604 was derived from. Both share the same YLRIVQCRSVEGSCGF amino-acid sequence in many supplier preparations \u2014 but the AOD-9604 designation specifically identifies the registered Metabolic-Pharmaceuticals compound. Users should consult the COA to confirm which form a given supplier batch corresponds to. <\/p>\n<h2>\u4f5c\u7528\u6a5f\u5e8f \u2014 GHR\u975e\u4f9d\u5b58\u6027\u8102\u80aa\u5206\u89e3<\/h2>\n<p>AOD-9604&#8217;s mechanism is among the most-discussed in HGH peptide studies:<\/p>\n<ul>\n<li><strong>GH\u53d7\u5bb9\u4f53\u7d50\u5408\u306e\u6b20\u5982<\/strong> \u2014 \u5929\u7136\u578bhGH\u306eGHR\u7d50\u5408\u8868\u9762\u306f\u3001\u5206\u5b50\u306eN\u672b\u7aef\u5074\u534a\u5206\uff08\u6b8b\u57fa1\uff5e120\u9818\u57df\uff09\u306b\u542b\u307e\u308c\u3066\u304a\u308a\u3001\u3053\u308c\u306fAOD-9604 \/ 176-191\u30d5\u30e9\u30b0\u30e1\u30f3\u30c8\u306b\u306f\u5b58\u5728\u3057\u307e\u305b\u3093\u3002\u305d\u306e\u7d50\u679c\u3001AOD-9604\u306f\u6210\u9577\u30db\u30eb\u30e2\u30f3\u53d7\u5bb9\u4f53\uff08GHR\uff09\u306b\u7d50\u5408\u305b\u305a\u3001JAK2\/STAT5\u30b7\u30b0\u30ca\u30eb\u4f1d\u9054\u3092\u6d3b\u6027\u5316\u305b\u305a\u3001\u809d\u81d3\u3067\u306eIGF-1\u7523\u751f\u3092\u8a98\u5c0e\u305b\u305a\u3001\u89aa <a href=\"https:\/\/medsbase.com\/ja\/hgh-191aa\/\">HGH 191AA<\/a> \u5206\u5b50\u3002\u3053\u308c\u304c\u6c7a\u5b9a\u7684\u306a <em>\u03b23\u30a2\u30c9\u30ec\u30ca\u30ea\u30f3\u53d7\u5bb9\u4f53\u30b7\u30b0\u30ca\u30eb\u4f1d\u9054\uff08\u4eee\u8aac\uff09<\/em> pharmacological property and the basis for AOD-9604&#8217;s studies utility as a lipolysis-axis-isolating tool.<\/li>\n<li><strong>\u03b23\u30a2\u30c9\u30ec\u30ca\u30ea\u30f3\u53d7\u5bb9\u4f53\u30b7\u30b0\u30ca\u30eb\u4f1d\u9054\uff08\u4eee\u8aac\uff09<\/strong> \u2014 The leading mechanistic hypothesis for AOD-9604&#8217;s lipolytic activity is that it engages the \u03b23-adrenergic receptor (ADRB3) on adipocytes, either directly as an allosteric modulator or via an intermediate pathway. Published in-vitro has demonstrated that AOD-9604&#8217;s lipolytic effect is blunted by \u03b23-adrenergic antagonists, supporting the \u03b23-AR hypothesis, although direct AOD-9604 \/ \u03b23-AR binding has not been conclusively demonstrated in radioligand-binding assays. The mechanism remains incompletely characterised \u2014 a feature users should be aware of when interpreting published AOD-9604 results.<\/li>\n<li><strong>\u30db\u30eb\u30e2\u30f3\u611f\u53d7\u6027\u30ea\u30d1\u30fc\u30bc\uff08HSL\uff09\u6d3b\u6027\u5316<\/strong> \u2014 AOD-9604\u306f\u8102\u80aa\u5206\u89e3\u3092\u4fc3\u9032\u3059\u308b\u3053\u3068\u306b\u52a0\u3048\u3066\u3001\u57f9\u990a\u8102\u80aa\u7d30\u80de\u306b\u304a\u3051\u308bde novo\u8102\u80aa\u5408\u6210\u3092\u6291\u5236\u3057\u30013T3-L1\u5206\u5316\u30a2\u30c3\u30bb\u30a4\u306b\u304a\u3044\u3066\u30a2\u30bb\u30c1\u30ebCoA\u30ab\u30eb\u30dc\u30ad\u30b7\u30e9\u30fc\u30bc\uff08ACC\uff09\u304a\u3088\u3073\u8102\u80aa\u9178\u5408\u6210\u9175\u7d20\uff08FAS\uff09\u306e\u6d3b\u6027\u3092\u4f4e\u4e0b\u3055\u305b\u308b\u3053\u3068\u304c\u5831\u544a\u3055\u308c\u3066\u3044\u307e\u3059\u3002\u3053\u306e\u8102\u80aa\u5206\u89e3\u4fc3\u9032\u3068\u8102\u80aa\u5408\u6210\u6291\u5236\u306e\u8907\u5408\u30d7\u30ed\u30d5\u30a1\u30a4\u30eb\u306f\u3001\u5f53\u521d\u306eMetabolic Pharmaceuticals\u793e\u306e\u30d7\u30ed\u30b0\u30e9\u30e0\u304c\u76ee\u6307\u3057\u305f\u6a19\u6e96\u7684\u306a\u300c\u8102\u80aa\u52d5\u54e1\u300d\u85ac\u7406\u5b66\u3067\u3059\u3002<\/li>\n<li><strong>\u6297\u8102\u80aa\u751f\u6210\u4f5c\u7528<\/strong> \u2014 AOD-9604\u306f\u3001\u8102\u80aa\u5206\u89e3\u3092\u4fc3\u9032\u3059\u308b\u3053\u3068\u306b\u52a0\u3048\u3066\u3001\u57f9\u990a\u8102\u80aa\u7d30\u80de\u306b\u304a\u3051\u308b\u30c7\u30ce\u30dc\u8102\u80aa\u5408\u6210\u3092\u6291\u5236\u3059\u308b\u3053\u3068\u304c\u5831\u544a\u3055\u308c\u3066\u3044\u307e\u3059\u30023T3-L1\u5206\u5316\u30a2\u30c3\u30bb\u30a4\u306b\u304a\u3044\u3066\u3001acetyl-CoA carboxylase (ACC)\u304a\u3088\u3073fatty-acid synthase (FAS)\u306e\u6d3b\u6027\u3092\u4f4e\u4e0b\u3055\u305b\u308b\u3053\u3068\u304c\u78ba\u8a8d\u3055\u308c\u3066\u3044\u307e\u3059\u3002\u3053\u306e\u8102\u80aa\u5206\u89e3\u4fc3\u9032\uff0f\u8102\u80aa\u5408\u6210\u6291\u5236\u306e\u7d44\u307f\u5408\u308f\u305b\u30d7\u30ed\u30d5\u30a1\u30a4\u30eb\u306f\u3001\u5f53\u521d\u306eMetabolic-Pharmaceuticals\u30d7\u30ed\u30b0\u30e9\u30e0\u304c\u4f5c\u7528\u6a19\u7684\u3068\u3057\u3066\u8a2d\u8a08\u3057\u305f\u3001\u5178\u578b\u7684\u306a\u300c\u8102\u80aa\u52d5\u54e1\u300d\u85ac\u7406\u4f5c\u7528\u3067\u3059\u3002<\/li>\n<li><strong>Cartilage \/ osteoarthritis studies (secondary indication)<\/strong> \u2014 Following the failure of the obesity programme, AOD-9604 was repositioned for evaluation in osteoarthritis studies, with the hypothesis that chondroprotective effects of the parent hGH might be partially retained in the C-terminal fragment. Published in-vitro and small-animal has reported chondrocyte-protective effects, although no large clinical trial in this indication has been completed.<\/li>\n<li><strong>4\u5206\u306e\u534a\u6e1b\u671f\u554f\u984c<\/strong> \u2014 AOD-9604&#8217;s plasma half-life is approximately 4 minutes, driven by rapid amino-terminal proteolytic truncation despite the N-terminal Tyr stabilisation. This very short pharmacokinetic profile is one of the leading hypotheses for why the Phase IIb obesity trial did not achieve weight-loss endpoints \u2014 the fragment is degraded before sufficient receptor exposure can accumulate in target adipose tissue under once-daily SC dosing. Newer peptides that target the same lipolysis-axis biology with longer half-lives (modified hGH fragments with PEG-stabilisation, fragment-Fc fusion proteins) are in earlier-stage studies and not commercially available.<\/li>\n<\/ul>\n<p>The combination of mechanistically clean GHR-decoupling and disappointing in-vivo half-life makes AOD-9604 a useful tool with a clear pharmacological story but a documented translational limitation. Published studies dosing in rodents is typically 100\u20131,000 \u00b5g\/kg\/d SC, with the higher end of this range used to overcome the short half-life by saturating clearance. In cell-culture work, micromolar concentrations are used because of the short biological half-life of the fragment in culture medium. <\/p>\n<h2>Published Evidence<\/h2>\n<p>AOD-9604 is used in clinical contexts that investigate:<\/p>\n<ul>\n<li><strong>GHR\u8131\u5171\u5f79\u8102\u80aa\u5206\u89e3\u85ac\u7406\u5b66<\/strong> \u2014 the canonical tool for studying the lipolytic \/ anti-lipogenic activity of the C-terminal hGH fragment in isolation from GH-axis signalling; standard reference compound for any new &#8220;fat-loss-only&#8221; hGH-fragment studies<\/li>\n<li><strong>Structure-function studies of HGH<\/strong> \u2014 AOD-9604 is one of the cleanest examples of pharmacological structure-function dissection of the multi-activity HGH molecule; used in published studies that maps the lipolytic-domain residues of native HGH<\/li>\n<li><strong>Adipocyte biology and lipolysis studies<\/strong> \u2014 drives lipolysis in cultured 3T3-L1 and primary adipocyte preparations; used in studies on the regulation of adipocyte hormone-sensitive lipase, lipid droplet remodelling, and brown \/ beige adipocyte biology<\/li>\n<li><strong>\u03b23\u30a2\u30c9\u30ec\u30ca\u30ea\u30f3\u53d7\u5bb9\u4f53\u85ac\u7406\u5b66\uff08\u9593\u63a5\u7684\uff09<\/strong> \u2014 AOD-9604&#8217;s \u03b23-AR-dependence (in some published studies) makes it useful as an indirect probe of \u03b23-AR-coupled lipolysis pathways, alongside direct \u03b23-AR agonists (CL-316,243, mirabegron)<\/li>\n<li><strong>Diet-induced obesity (DIO) rodent studies<\/strong> \u2014 published 4\u20138 week dosing protocols (100\u20131,000 \u00b5g\/kg\/d SC) in DIO mice and rats have been reported to reduce fat-mass without affecting lean-mass or IGF-1 levels; standard tool for the &#8220;lipolytic-only&#8221; component of fat-loss pharmacology<\/li>\n<li><strong>Cartilage \/ chondrocyte studies<\/strong> \u2014 used in published in-vitro chondrocyte and small-animal osteoarthritis models for chondroprotective evaluation; secondary studies indication following the discontinuation of the obesity programme<\/li>\n<li><strong>HGH 191AA\u304a\u3088\u3073HGH Fragment 176-191\u3068\u306e\u6bd4\u8f03\u85ac\u7406<\/strong> \u2014 \u516c\u958b\u3055\u308c\u305fAOD-9604\u3068\u5168\u9577HGH\u304a\u3088\u3073\u975e\u5b89\u5b9a\u5316176-191\u30d5\u30e9\u30b0\u30e1\u30f3\u30c8\u3068\u306e\u76f4\u63a5\u6bd4\u8f03\u8a66\u9a13\u3067\u306f\u3001\u7570\u306a\u308bGHR\u7d50\u5408\u6027\u3001IGF-1\u8a98\u5c0e\u6027\u3001\u8102\u80aa\u5206\u89e3\u30d7\u30ed\u30d5\u30a1\u30a4\u30eb\u304c\u660e\u3089\u304b\u306b\u3055\u308c\u3066\u3044\u307e\u3059\uff1bAOD-9604\u306f\u3001\u3053\u306e\u30b9\u30da\u30af\u30c8\u30e9\u30e0\u306b\u304a\u3044\u3066\u300c\u8102\u80aa\u5206\u89e3\u306e\u307f\u3001\u6210\u9577\u8ef8\u306a\u3057\u300d\u306e\u6975\u7aef\u306a\u4f4d\u7f6e\u306b\u3042\u308a\u307e\u3059\u3002<\/li>\n<li><strong>Plasma-stability and protease-resistance studies<\/strong> \u2014 the 4-minute half-life makes AOD-9604 a useful reference compound for protease-resistance studies; newer modified analogues (PEG-stabilised, fragment-Fc fusion, alternative N-terminal cap modifications) are benchmarked against AOD-9604 in early-stage development studies<\/li>\n<\/ul>\n<p>For broader context on HGH-axis and fat-loss peptides in this catalogue, see <a href=\"https:\/\/medsbase.com\/ja\/hgh-fragment-176-191\/\">HGH\u30d5\u30e9\u30b0\u30e1\u30f3\u30c8176-191<\/a> \uff08\u975e\u5b89\u5b9a\u5316\u89aa\u30d5\u30e9\u30b0\u30e1\u30f3\u30c8 \u2014 \u76f4\u63a5\u6bd4\u8f03\uff09\u3001, <a href=\"https:\/\/medsbase.com\/ja\/hgh-191aa\/\">HGH 191AA<\/a> \uff08\u5168\u9577\u306e\u89aa\u5206\u5b50 \u2014 \u6bd4\u8f03\u85ac\u7406\u5b66\u306e\u305f\u3081\uff09, <a href=\"https:\/\/medsbase.com\/ja\/tesamorelin\/\">Tesamorelin<\/a> \uff08GHRH\u30a2\u30ca\u30ed\u30b0 \u2014 \u4e0a\u6d41\u306eHGH\u8ef8\u523a\u6fc0\uff09\u3001, <a href=\"https:\/\/medsbase.com\/ja\/sermorelin\/\">Sermorelin<\/a> \uff08GHRH 1-29\u30a2\u30ca\u30ed\u30b0\uff09\u3001\u304a\u3088\u3073 <a href=\"https:\/\/medsbase.com\/ja\/mots-c\/\">MOTS-c<\/a> \uff08\u30df\u30c8\u30b3\u30f3\u30c9\u30ea\u30a2\u7531\u6765\u4ee3\u8b1d\u30da\u30d7\u30c1\u30c9\uff09\u3002\u5168\u30e9\u30a4\u30f3\u30ca\u30c3\u30d7\u3092\u898b\u308b <a href=\"https:\/\/medsbase.com\/ja\/peptides\/\">peptides &amp; compounds catalog<\/a>, \u3001\u307e\u305f\u306f\u53b3\u9078\u3055\u308c\u305f <a href=\"https:\/\/medsbase.com\/ja\/best-peptides-for-fat-loss\/\">fat-loss peptides<\/a> KYC\uff08Know Your Customer\uff09 <a href=\"https:\/\/medsbase.com\/ja\/best-growth-hormone-peptides\/\">growth-hormone peptides<\/a> \u30cf\u30d6\u3002 <\/p>\n<h2>\u5229\u7528\u53ef\u80fd\u306a\u529b\u4fa1\u3068\u6fc3\u5ea6<\/h2>\n<p>MedsBase stocks AOD-9604 in three lyophilized vial sizes calibrated to typical in-vitro and in-vivo protocols. Each strength is available in 10-vial, 20-vial, or 30-vial pack formats:<\/p>\n<table style=\"width: 100%; border-collapse: collapse; margin: 16px 0;\">\n<thead>\n<tr style=\"background: #2c7cb0; color: #fff;\">\n<th style=\"padding: 10px; border: 1px solid #ddd; text-align: left;\">\u30d0\u30a4\u30a2\u30eb\u529b\u4fa1<\/th>\n<th style=\"padding: 10px; border: 1px solid #ddd; text-align: left;\">\u4ee3\u8868\u7684\u306a\u4f7f\u7528\u4f8b<\/th>\n<th style=\"padding: 10px; border: 1px solid #ddd; text-align: left;\">\u30d1\u30c3\u30af\u30b5\u30a4\u30ba<\/th>\n<\/tr>\n<\/thead>\n<tbody>\n<tr>\n<td style=\"padding: 10px; border: 1px solid #ddd;\"><strong>2 mg<\/strong><\/td>\n<td style=\"padding: 10px; border: 1px solid #ddd;\">in vitro\u7d30\u80de\u57f9\u990a\u304a\u3088\u3073\u77ed\u671f\u306ein vivo\u7528\u91cf\u8a2d\u5b9a \u2014 3T3-L1\u8102\u80aa\u7d30\u80de\u8102\u80aa\u5206\u89e3\u30a2\u30c3\u30bb\u30a4\u3001\u521d\u4ee3\u8102\u80aa\u7d30\u80de\u85ac\u7406\u5b66\u3001\u7528\u91cf\u53cd\u5fdc\u30d1\u30cd\u30eb\u3001\u5358\u4e00\u30b3\u30db\u30fc\u30c8\u30de\u30a6\u30b9\u7528\u91cf\u8a2d\u5b9a<\/td>\n<td style=\"padding: 10px; border: 1px solid #ddd;\">10\u300120\u3001\u307e\u305f\u306f30\u30d0\u30a4\u30a2\u30eb<\/td>\n<\/tr>\n<tr style=\"background: #f9f9f9;\">\n<td style=\"padding: 10px; border: 1px solid #ddd;\"><strong>5 mg<\/strong><\/td>\n<td style=\"padding: 10px; border: 1px solid #ddd;\">Standard mid-strength \u2014 diet-induced obesity rodent protocols (100\u2013500 \u00b5g\/kg\/d SC for 4\u20138 weeks), chondrocyte \/ osteoarthritis studies, multi-cohort sample sizes<\/td>\n<td style=\"padding: 10px; border: 1px solid #ddd;\">10\u300120\u3001\u307e\u305f\u306f30\u30d0\u30a4\u30a2\u30eb<\/td>\n<\/tr>\n<tr>\n<td style=\"padding: 10px; border: 1px solid #ddd;\"><strong>10 mg<\/strong><\/td>\n<td style=\"padding: 10px; border: 1px solid #ddd;\">High-strength vial \u2014 extended-cycle \/ high-dose protocols (up to 1 mg\/kg\/d SC), large-cohort DIO studies, multi-arm structure-function comparisons; lowest per-mg cost<\/td>\n<td style=\"padding: 10px; border: 1px solid #ddd;\">10\u300120\u3001\u307e\u305f\u306f30\u30d0\u30a4\u30a2\u30eb<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n<p>All three strengths are the same chemical entity (lyophilized AOD-9604, \u226599% HPLC purity, MALDI-TOF mass-confirmed at 1815.1 Da). The 10\u00a0mg vial provides the lowest per-mg cost for large in-vivo protocols (a single 10\u00a0mg vial supports approximately 50 days of 200 \u00b5g\/kg\/d dosing in a 25-g mouse, or about 10 days at 1\u00a0mg\/kg\/d in a 30-g rat). Users should determine specific dose ranges from peer-reviewed literature appropriate to the protocol. <\/p>\n<h2>\u6bd4\u8f03 \u2014 AOD-9604 vs HGH Fragment 176-191<\/h2>\n<p>AOD-9604\u304a\u3088\u3073 <a href=\"https:\/\/medsbase.com\/ja\/hgh-fragment-176-191\/\">HGH\u30d5\u30e9\u30b0\u30e1\u30f3\u30c8176-191<\/a> are the two HGH C-terminal fragment peptides in this catalogue, and they sit very close together on the structure-function spectrum. AOD-9604 is the Metabolic-Pharmaceuticals-developed analogue with the N-terminal tyrosine extension that adds protease-stability. The un-stabilised HGH Fragment 176-191 lacks the N-terminal Tyr and has a slightly shorter half-life in culture \/ in-vivo, but is otherwise mechanistically identical. The two compounds are often used interchangeably in supplier listings \u2014 the differentiation matters for rigorous pharmacology studies, less so for cell-culture stimulation work. <\/p>\n<table style=\"width: 100%; border-collapse: collapse; margin: 16px 0;\">\n<thead>\n<tr style=\"background: #2c7cb0; color: #fff;\">\n<th style=\"padding: 10px; border: 1px solid #ddd; text-align: left;\">\u8a55\u4fa1\u9805\u76ee<\/th>\n<th style=\"padding: 10px; border: 1px solid #ddd; text-align: left;\">AOD-9604<\/th>\n<th style=\"padding: 10px; border: 1px solid #ddd; text-align: left;\">HGH\u30d5\u30e9\u30b0\u30e1\u30f3\u30c8176-191<\/th>\n<\/tr>\n<\/thead>\n<tbody>\n<tr>\n<td style=\"padding: 10px; border: 1px solid #ddd;\"><strong>CAS\u756a\u53f7<\/strong><\/td>\n<td style=\"padding: 10px; border: 1px solid #ddd;\">221231-10-3<\/td>\n<td style=\"padding: 10px; border: 1px solid #ddd;\">66004-57-7<\/td>\n<\/tr>\n<tr style=\"background: #f9f9f9;\">\n<td style=\"padding: 10px; border: 1px solid #ddd;\"><strong>\u914d\u5217\uff08\u4e00\u6587\u5b57\u8868\u8a18\uff09<\/strong><\/td>\n<td style=\"padding: 10px; border: 1px solid #ddd;\">YLRIVQCRSVEGSCGF\uff0816\u30a2\u30df\u30ce\u9178\uff1bN\u672b\u7aefTyr\u5b89\u5b9a\u5316\u3042\u308a\uff09<\/td>\n<td style=\"padding: 10px; border: 1px solid #ddd;\">YLRIVQCRSVEGSCGF\uff0816\u30a2\u30df\u30ce\u9178\uff09\u307e\u305f\u306fLRIVQCRSVEGSCGF\uff0815\u30a2\u30df\u30ce\u9178\u3001\u975e\u5b89\u5b9a\u5316\uff09\u30b5\u30d7\u30e9\u30a4\u30e4\u30fc\u306e\u30d0\u30c3\u30c1\u306b\u3088\u308a\u7570\u306a\u308a\u307e\u3059\uff1bCOA\u3092\u3054\u78ba\u8a8d\u304f\u3060\u3055\u3044\u3002<\/td>\n<\/tr>\n<tr>\n<td style=\"padding: 10px; border: 1px solid #ddd;\"><strong>\u5206\u5b50\u91cf<\/strong><\/td>\n<td style=\"padding: 10px; border: 1px solid #ddd;\">1815.1 g\/mol<\/td>\n<td style=\"padding: 10px; border: 1px solid #ddd;\">1817.06 g\/mol\uff0816\u30a2\u30df\u30ce\u9178\u3001\u5546\u696d\u30b0\u30ec\u30fc\u30c9\uff09\u307e\u305f\u306f 1654 g\/mol\uff0815\u30a2\u30df\u30ce\u9178\u3001\u672a\u5b89\u5b9a\u5316\uff09<\/td>\n<\/tr>\n<tr style=\"background: #f9f9f9;\">\n<td style=\"padding: 10px; border: 1px solid #ddd;\"><strong>\u7531\u6765<\/strong><\/td>\n<td style=\"padding: 10px; border: 1px solid #ddd;\">Metabolic Pharmaceuticals Ltd\uff08\u30aa\u30fc\u30b9\u30c8\u30e9\u30ea\u30a2\u3001\u30e2\u30ca\u30c3\u30b7\u30e5\u5927\u5b66\u30011990\u5e74\u4ee3\u5f8c\u534a\uff09<\/td>\n<td style=\"padding: 10px; border: 1px solid #ddd;\">Earlier academic studies-peptide preparation, pre-dating AOD-9604<\/td>\n<\/tr>\n<tr>\n<td style=\"padding: 10px; border: 1px solid #ddd;\"><strong>\u8840\u6f3f\u4e2d\u534a\u6e1b\u671f<\/strong><\/td>\n<td style=\"padding: 10px; border: 1px solid #ddd;\">\u7d044\u5206<\/td>\n<td style=\"padding: 10px; border: 1px solid #ddd;\">\u7d042\uff5e3\u5206\uff08\u3088\u308a\u77ed\u304f\u3001\u30d7\u30ed\u30c6\u30a2\u30fc\u30bc\u5b89\u5b9a\u6027\u304c\u4f4e\u3044\uff09<\/td>\n<\/tr>\n<tr style=\"background: #f9f9f9;\">\n<td style=\"padding: 10px; border: 1px solid #ddd;\"><strong>GH\u53d7\u5bb9\u4f53\u7d50\u5408<\/strong><\/td>\n<td style=\"padding: 10px; border: 1px solid #ddd;\">\u306a\u3057 \u2014 GHR\/JAK2\/STAT5\/IGF-1\u7d4c\u8def\u306b\u95a2\u4e0e\u3057\u307e\u305b\u3093\u3002<\/td>\n<td style=\"padding: 10px; border: 1px solid #ddd;\">\u306a\u3057 \u2014 \u540c\u69d8\u306e\u7279\u6027\uff1b\u3044\u305a\u308c\u3082GHR\u304b\u3089\u5207\u308a\u96e2\u3055\u308c\u305f\u65ad\u7247\u3067\u3059\u3002<\/td>\n<\/tr>\n<tr>\n<td style=\"padding: 10px; border: 1px solid #ddd;\"><strong>\u81e8\u5e8a\u8a66\u9a13\u306e\u5c65\u6b74<\/strong><\/td>\n<td style=\"padding: 10px; border: 1px solid #ddd;\">\u7b2cIIb\u76f8\u80a5\u6e80\u8a66\u9a13\uff08\u7d04500\u4f8b\u30012007\u5e74\uff09\u306f\u4e3b\u8981\u8a55\u4fa1\u9805\u76ee\u3092\u9054\u6210\u305b\u305a\u3001\u30d7\u30ed\u30b0\u30e9\u30e0\u306f\u4e2d\u6b62\u3055\u308c\u307e\u3057\u305f\u3002<\/td>\n<td style=\"padding: 10px; border: 1px solid #ddd;\">\u6b63\u5f0f\u306a\u81e8\u5e8a\u958b\u767a\u30d7\u30ed\u30b0\u30e9\u30e0\u306f\u3042\u308a\u307e\u305b\u3093\u3002<\/td>\n<\/tr>\n<tr style=\"background: #f9f9f9;\">\n<td style=\"padding: 10px; border: 1px solid #ddd;\"><strong>Best applications<\/strong><\/td>\n<td style=\"padding: 10px; border: 1px solid #ddd;\">\u534a\u6e1b\u671f\u304c\u308f\u305a\u304b\u306b\u9577\u3044\u305f\u3081in vivo\u7814\u7a76\u3067\u3084\u3084\u597d\u307e\u308c\u3001\u69cb\u9020-\u6a5f\u80fd\u6bd4\u8f03\u306e\u305f\u3081\u306e\u53c2\u7167\u5316\u5408\u7269\u3068\u3057\u3066\u4f7f\u7528\u3055\u308c\u307e\u3059\u3002<\/td>\n<td style=\"padding: 10px; border: 1px solid #ddd;\">\u534a\u6e1b\u671f\u306e\u77ed\u3055\u304c\u3042\u307e\u308a\u5236\u9650\u306b\u306a\u3089\u306a\u3044in vitro\u7d30\u80de\u57f9\u990a\u30ea\u30dd\u30ea\u30b7\u30b9\u30a2\u30c3\u30bb\u30a4<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n<p>For studies focused on rigorous structure-function HGH-fragment pharmacology, AOD-9604 with its registered CAS \/ known origin is the cleaner reference. For exploratory in-vitro lipolysis work where the precise origin matters less, <a href=\"https:\/\/medsbase.com\/ja\/hgh-fragment-176-191\/\">HGH\u30d5\u30e9\u30b0\u30e1\u30f3\u30c8176-191<\/a> is the more economical option. For studies that needs the full HGH pharmacology including GH-receptor \/ IGF-1 axis engagement, see <a href=\"https:\/\/medsbase.com\/ja\/hgh-191aa\/\">HGH 191AA<\/a>. <\/p>\n<div style=\"background: #f4f8fb; border-left: 4px solid #2c7cb0; padding: 14px 18px; margin: 18px 0;\"><strong class=\"mb-bac-water-callout\">\ud83d\udca7 BAC\u6c34\u304c\u5fc5\u8981\u3067\u3059\u304b\uff1f<\/strong> \u51cd\u7d50\u4e7e\u71e5\u54c1\u306e\u5fa9\u5143\u306b\u306f\u6ec5\u83cc\u9759\u83cc\u6c34\u304c\u5fc5\u8981\u3067\u3059\u3002\u672c\u88fd\u54c1\u3068\u4f75\u305b\u3066\u5f53\u793e\u306e <a href=\"\/ja\/bac-water\/\"><strong>BAC Water\uff08\u9759\u83cc\u6c34\uff09<\/strong><\/a> \u2014 30 mL\u30de\u30eb\u30c1\u30c9\u30fc\u30ba\u30d0\u30a4\u30a2\u30eb\u30010.9%\u30d9\u30f3\u30b8\u30eb\u30a2\u30eb\u30b3\u30fc\u30eb\u4fdd\u5b58\u3001USP\u30b0\u30ec\u30fc\u30c9\u3002<\/div>\n<h2>\u4fdd\u7ba1\u65b9\u6cd5\u3068\u518d\u6eb6\u89e3<\/h2>\n<p><strong>\u518d\u6eb6\u89e3\u524d\uff1a<\/strong> \u77ed\u671f\u4f7f\u7528\u306e\u30ef\u30fc\u30ad\u30f3\u30b0\u30b9\u30c8\u30c3\u30af\u306b\u306f\u3001\u51cd\u7d50\u4e7e\u71e5\u30d0\u30a4\u30a2\u30eb\u3092\u5143\u306e\u5305\u88c5\u306e\u307e\u307e2\uff5e8 \u00b0C\u3067\u51b7\u8535\u4fdd\u5b58\u3057\u3066\u304f\u3060\u3055\u3044\u3002\u9577\u671f\u4fdd\u5b58\u306e\u5834\u5408\u306f\u3001\u672a\u958b\u5c01\u306e\u30d0\u30a4\u30a2\u30eb\u3092\u221220 \u00b0C\u3067\u51cd\u7d50\u4fdd\u5b58\u3057\u3066\u304f\u3060\u3055\u3044\uff08\u221220 \u00b0C\u306736\u304b\u6708\u4ee5\u4e0a\u5b89\u5b9a\u30012\uff5e8 \u00b0C\u306718\u304b\u6708\u4ee5\u4e0a\u5b89\u5b9a\uff09\u3002Cys7\u2013Cys14\u30b8\u30b9\u30eb\u30d5\u30a3\u30c9\u67b6\u6a4b\u306f\u51cd\u7d50\u4e7e\u71e5\u72b6\u614b\u304a\u3088\u3073\u77ed\u671f\u306e\u51b7\u8535\u4fdd\u5b58\u4e2d\u306b\u5b89\u5b9a\u3067\u3059\u3002\u5149\u304b\u3089\u4fdd\u8b77\u3057\u3066\u304f\u3060\u3055\u3044\u3002 <strong>\u518d\u6eb6\u89e3\u624b\u9806\uff1a<\/strong> \u30d0\u30a4\u30a2\u30eb\u306e\u5074\u58c1\u306b\u6cbf\u3063\u3066\u9759\u83cc\u6c34\u3092\u6ce8\u5165\u3057\u3066\u304f\u3060\u3055\u3044\uff08\u51cd\u7d50\u4e7e\u71e5\u30b1\u30fc\u30ad\u306b\u76f4\u63a5\u304b\u3051\u306a\u3044\u3067\u304f\u3060\u3055\u3044\uff09\u30022 mg\u30d0\u30a4\u30a2\u30eb\u3067\u306f\u3001\u5e0c\u91c8\u6db21.0 mL\u30672 mg\/mL\u306e\u30ef\u30fc\u30ad\u30f3\u30b0\u30b9\u30c8\u30c3\u30af\u30010.5 mL\u30674 mg\/mL\u306b\u306a\u308a\u307e\u3059\u30025 mg\u30d0\u30a4\u30a2\u30eb\u3067\u306f\u30011.0 mL\u30675 mg\/mL\u30012.5 mL\u30672 mg\/mL\u306b\u306a\u308a\u307e\u3059\u300210 mg\u30d0\u30a4\u30a2\u30eb\u3067\u306f\u30011.0 mL\u306710 mg\/mL\uff08\u6c34\u6027\u7de9\u885d\u6db2\u4e2d\u306e\u5b9f\u7528\u7684\u6eb6\u89e3\u5ea6\u9650\u754c\uff09\u30015.0 mL\u30672 mg\/mL\u306b\u306a\u308a\u307e\u3059\u3002AOD-9604\u306f\u5ba4\u6e29\u3067\u7a4f\u3084\u304b\u306b\u65cb\u56de\u3055\u305b\u308b\u3053\u3068\u3067\u6025\u901f\u306b\u6eb6\u89e3\u3057\u307e\u3059 \u2014 \u901a\u5e3815\u301c30\u79d2\u4ee5\u5185\u3067\u3059\u3002\u518d\u69cb\u6210\u5f8c\u306f\u3001\u30d0\u30a4\u30a2\u30eb\u30922\uff5e8 \u00b0C\u3067\u4fdd\u5b58\u3057\u300130\u65e5\u4ee5\u5185\u306b\u4f7f\u7528\u3057\u3066\u304f\u3060\u3055\u3044\u3002\u5149\u304b\u3089\u4fdd\u8b77\u3057\u3066\u304f\u3060\u3055\u3044\u3002 <strong>\u518d\u69cb\u6210\u6e08\u307f\u306e\u6750\u6599\u306e\u51cd\u7d50\u878d\u89e3\u306e\u7e70\u308a\u8fd4\u3057\u3092\u907f\u3051\u3066\u304f\u3060\u3055\u3044<\/strong> \u2014 \u51cd\u7d50\u878d\u89e3\u3092\u7e70\u308a\u8fd4\u3059\u3068\u3001Cys7\u2013Cys14\u30b8\u30b9\u30eb\u30d5\u30a3\u30c9\u306e\u30b9\u30af\u30e9\u30f3\u30d6\u30ea\u30f3\u30b0\u3068\u90e8\u5206\u7684\u51dd\u96c6\u306e\u30ea\u30b9\u30af\u304c\u7d2f\u7a4d\u3057\u307e\u3059\u3002\u6fc1\u308a\u3001\u7c92\u5b50\u3001\u307e\u305f\u306f\u8457\u3057\u3044\u8272\u306e\u5909\u5316\u304c\u73fe\u308c\u305f\u5834\u5408\u306f\u5ec3\u68c4\u3057\u3066\u304f\u3060\u3055\u3044\u3002 <\/p>\n<h2>\u3088\u304f\u3042\u308b\u8cea\u554f<\/h2>\n<h3>AOD-9604\u3068HGH Fragment 176-191\u306e\u9055\u3044\u306f\u4f55\u3067\u3059\u304b\uff1f<\/h3>\n<p>AOD-9604 (CAS 221231-10-3) is the Metabolic-Pharmaceuticals-developed registered compound with an N-terminal tyrosine extension that adds amino-terminal protease-stability to the parent hGH 177\u2013191 fragment. &#8220;<a href=\"https:\/\/medsbase.com\/ja\/hgh-fragment-176-191\/\">HGH\u30d5\u30e9\u30b0\u30e1\u30f3\u30c8176-191<\/a>&#8221; (CAS 66004-57-7 per some references) is the earlier, un-stabilised version of the same C-terminal hGH peptide. The two are often used interchangeably in the studies-peptide marketplace, but strictly the AOD-9604 designation identifies the Metabolic-Pharmaceuticals registered analogue with the stabilising Tyr. Both lack GHR binding and both retain the lipolytic activity of the parent hGH C-terminal region. Consult the COA to confirm which sequence form a given batch corresponds to. <\/p>\n<h3>AOD-9604\u306fHGH\u3068\u540c\u3058\u3067\u3059\u304b\uff1f<\/h3>\n<p>\u3044\u3044\u3048\u3002AOD-9604\u306fHGH\u306e16\u30a2\u30df\u30ce\u9178\u306e\u5408\u6210\u30d5\u30e9\u30b0\u30e1\u30f3\u30c8\u3067\u3001C\u672b\u7aef\u306e\u30ea\u30dd\u30ea\u30b7\u30b9\u9818\u57df\uff08\u6b8b\u57fa176-191 + N\u672b\u7aefTyr\uff09\u306e\u307f\u3092\u30ab\u30d0\u30fc\u3057\u3066\u3044\u307e\u3059\u3002\u30cd\u30a4\u30c6\u30a3\u30d6 <a href=\"https:\/\/medsbase.com\/ja\/hgh-191aa\/\">HGH 191AA<\/a> is the full-length 191-amino-acid protein. The most important pharmacological difference is that full-length HGH binds the growth hormone receptor (GHR) and activates the JAK2\/STAT5\/IGF-1 axis \u2014 driving the broad growth-promoting and metabolic effects of HGH \u2014 while AOD-9604 does NOT bind GHR and does NOT induce IGF-1. AOD-9604 retains only the lipolytic \/ anti-lipogenic activity of the parent molecule. The two compounds are therefore mechanistically distinct: HGH 191AA for full GH-axis pharmacology, AOD-9604 for lipolysis-only studies. <\/p>\n<h3>\u7b2cIIb\u76f8\u80a5\u6e80\u8a66\u9a13\u304c\u5931\u6557\u3057\u305f\u306e\u306f\u306a\u305c\u3067\u3059\u304b\uff1f<\/h3>\n<p>The 28-week Phase IIb obesity trial (~500 patients, completed by Metabolic Pharmaceuticals in 2007) did not achieve its primary weight-loss endpoint relative to placebo. The leading hypotheses in subsequent published analyses are: (1) the very short plasma half-life (~4 minutes) limits cumulative receptor exposure under once-daily SC dosing; (2) the lipolytic effect, while real in mechanistic in-vitro and acute in-vivo experiments, may not translate to net adipose-mass loss in the human metabolic context where compensatory anti-lipolytic signalling dominates over chronic dosing; (3) the in-vivo dose may have been insufficient to overcome the pharmacokinetic constraint. The compound was repositioned for osteoarthritis studies after the obesity programme was discontinued. <\/p>\n<h3>What published dose ranges have been used in rodent studies?<\/h3>\n<p>Published mouse and rat in-vivo protocols typically use 100\u20131,000 \u00b5g\/kg\/d SC, with most published work in the 200\u2013500 \u00b5g\/kg\/d range for 4\u20138 weeks. The higher end of this range (up to 1 mg\/kg\/d) has been used in some publications to overcome the short half-life. In-vitro 3T3-L1 adipocyte assays typically use 1\u201310 \u00b5M. Users should consult primary literature (Ng et\u00a0al. \u2014 Metabolic Pharmaceuticals studies; Heffernan et\u00a0al. \u2014 adipocyte mechanism studies) for species-, model-, and endpoint-specific guidance. <\/p>\n<h3>AOD-9604\u306eWADA\u898f\u5236\u4e0a\u306e\u30b9\u30c6\u30fc\u30bf\u30b9\u306f\u4f55\u3067\u3059\u304b\uff1f<\/h3>\n<p>AOD-9604 is not on the current WADA Prohibited List under its specific name. However, the broader S2 class (Peptide Hormones, Growth Factors, Related Substances and Mimetics) explicitly covers growth-hormone fragments and &#8220;GH-axis-related compounds,&#8221; and AOD-9604&#8217;s classification under this broader category has been the subject of regulatory discussion. Users conducting human-subject studies with AOD-9604 should consult the current WADA Prohibited List and applicable jurisdictional regulations directly rather than relying on the absence of a specific name from the list. <\/p>\n<h3>AOD-9604\u3068\u30df\u30e9\u30d9\u30b0\u30ed\u30f3\u306e\u3088\u3046\u306a\u76f4\u63a5\u7684\u306a\u03b23\u30a2\u30c9\u30ec\u30ca\u30ea\u30f3\u53d7\u5bb9\u4f53\u4f5c\u52d5\u85ac\u3068\u306e\u9055\u3044\u306f\u4f55\u3067\u3059\u304b\uff1f<\/h3>\n<p>\u30df\u30e9\u30d9\u30b0\u30ed\u30f3\u304a\u3088\u3073CL-316,243\u306f <em>\u76f4\u63a5\u7684\u306a<\/em> \u03b23\u30a2\u30c9\u30ec\u30ca\u30ea\u30f3\u53d7\u5bb9\u4f53\u4f5c\u52d5\u85ac \u2014 \u03b23-AR\u306e\u30aa\u30eb\u30bd\u30b9\u30c6\u30ea\u30c3\u30af\u90e8\u4f4d\u306b\u7d50\u5408\u3057\u3001Gs-cAMP\u30b7\u30b0\u30ca\u30eb\u4f1d\u9054\u3092\u6d3b\u6027\u5316\u3059\u308b\u4f4e\u5206\u5b50\u3067\u3059\u3002AOD-9604\u306f\uff08\u4e00\u90e8\u306e\u516c\u8868\u7814\u7a76\u306b\u304a\u3044\u3066\uff09 <em>\u9593\u63a5\u7684<\/em> \u03b23-AR engager (in some published studies) \u2014 the lipolytic activity is blunted by \u03b23-AR antagonists, supporting \u03b23-AR-dependence, but direct AOD-9604 \/ \u03b23-AR binding has not been conclusively demonstrated. For studies that needs cleanly defined direct \u03b23-AR pharmacology, mirabegron or CL-316,243 are the preferred tools. For studies that needs the broader &#8220;lipolytic-fragment-of-HGH&#8221; pharmacology with its incompletely-characterised mechanism, AOD-9604 is the canonical reference. <\/p>\n<h3>Can AOD-9604 be combined with HGH 191AA, GHRH analogues, or other lipolytic peptides in protocols?<\/h3>\n<p>\u53ef\u80fd\u3067\u3059 \u2014 AOD-9604\u306f\u3001\u5b8c\u5168\u9577\u306e <a href=\"https:\/\/medsbase.com\/ja\/hgh-191aa\/\">HGH 191AA<\/a> \u3084GHRH\u30a2\u30ca\u30ed\u30b0\uff08<a href=\"https:\/\/medsbase.com\/ja\/tesamorelin\/\">Tesamorelin<\/a>, <a href=\"https:\/\/medsbase.com\/ja\/sermorelin\/\">Sermorelin<\/a>), and combinations are commonly used in published studies to dissect lipolytic-only contributions from broader GH-axis effects. The most-published combinations are AOD-9604 + HGH 191AA (testing whether the lipolytic component adds to or substracts from full HGH activity); AOD-9604 + <a href=\"https:\/\/medsbase.com\/ja\/mots-c\/\">MOTS-c<\/a> (dual fat-loss studies, different mechanisms); AOD-9604 + a GHRH analogue (testing whether endogenous-pulsatile HGH release combined with the lipolytic fragment outperforms either alone). Reconstitute each separately and follow each compound&#8217;s specific storage rules. <\/p>\n<h3>AOD-9604\u306e\u5206\u5b50\u91cf\u304c1815.1 Da\u3068\u8a18\u8f09\u3055\u308c\u308b\u5834\u5408\u30681817 Da\u3068\u8a18\u8f09\u3055\u308c\u308b\u5834\u5408\u304c\u3042\u308b\u306e\u306f\u306a\u305c\u3067\u3059\u304b\uff1f<\/h3>\n<p>\u3053\u306e\u4e0d\u4e00\u81f4\u306f\u3001\u30e2\u30ce\u30a2\u30a4\u30bd\u30c8\u30d4\u30c3\u30af\u8cea\u91cf\uff081815.1 Da\u3001\u5404\u539f\u5b50\u306e\u6700\u3082\u5b58\u5728\u6bd4\u306e\u9ad8\u3044\u540c\u4f4d\u4f53\u304b\u3089\u8a08\u7b97\uff09\u3068\u5e73\u5747\u5206\u5b50\u91cf\uff081817.1 Da\u3001\u5404\u539f\u5b50\u306e\u5929\u7136\u540c\u4f4d\u4f53\u5b58\u5728\u6bd4\u3067\u91cd\u307f\u4ed8\u3051\u3057\u305f\u5e73\u5747\u8cea\u91cf\u304b\u3089\u8a08\u7b97\uff09\u306e\u9055\u3044\u3092\u53cd\u6620\u3057\u3066\u3044\u307e\u3059\u3002\u3069\u3061\u3089\u3082\u540c\u3058\u5206\u5b50\u306b\u5bfe\u3057\u3066\u6b63\u3057\u3044\u5024\u3067\u3059\u3002\u3053\u306e\u30b5\u30a4\u30ba\u306e\u30da\u30d7\u30c1\u30c9\u3067\u306f\u3001MALDI-TOF\u8cea\u91cf\u5206\u6790\u306f\u901a\u5e38\u30e2\u30ce\u30a2\u30a4\u30bd\u30c8\u30d4\u30c3\u30af\u8cea\u91cf\u3092\u5831\u544a\u3057\u307e\u3059\u304c\u3001\u53e4\u3044\u6587\u732e\u3084\u4e00\u90e8\u306e\u30b5\u30d7\u30e9\u30a4\u30e4\u30fc\u306f\u5e73\u5747\u8cea\u91cf\u3092\u5831\u544a\u3057\u307e\u3059\u3002COA\u306e\u76ee\u7684\u3067\u306f\u30011815.1 Da\u306e\u6570\u5024\u304cSigma-Aldrich\u306e\u6a19\u6e96\u7684\u306a\u53c2\u7167\u5024\u3067\u3059\u3002 <!-- medsbase-related-alts-v1 --><\/p>\n<h2>Other Peptides for HGH-Axis and Fat-Loss Studies<\/h2>\n<ul>\n<li><a href=\"\/ja\/hgh-fragment-176-191\/\"><strong>HGH\u30d5\u30e9\u30b0\u30e1\u30f3\u30c8176-191<\/strong><\/a> \u2014 \u5b89\u5b9a\u5316\u3055\u308c\u3066\u3044\u306a\u3044\u89aa\u30d5\u30e9\u30b0\u30e1\u30f3\u30c8 \u2014 \u76f4\u63a5\u7684\u306a\u6a5f\u5e8f\u306e\u985e\u7e01\u4f53\u3067\u3042\u308a\u3001GHR\u975e\u4f9d\u5b58\u6027\u306e\u8102\u80aa\u5206\u89e3\u304c\u985e\u4f3c\u3057\u3066\u3044\u307e\u3059\u3002<\/li>\n<li><a href=\"\/ja\/hgh-191aa\/\"><strong>HGH 191AA<\/strong><\/a> \u2014 \u5168\u9577\u306e\u89aa\u5206\u5b50 \u2014 GH\u8ef8\u306e\u95a2\u4e0e\u3092\u4f34\u3046\u6bd4\u8f03\u85ac\u7406\u5b66\u306e\u305f\u3081\u306e\u3082\u306e\u3067\u3059\u3002<\/li>\n<li><a href=\"\/ja\/tesamorelin\/\"><strong>Tesamorelin<\/strong><\/a> \u2014 GHRH\u30a2\u30ca\u30ed\u30b0 \u2014 \u4e0a\u6d41\u306eHGH\u8ef8\u523a\u6fc0\u306e\u305f\u3081\u306e\u3082\u306e\u3067\u3059\u3002<\/li>\n<li><a href=\"\/ja\/sermorelin\/\"><strong>Sermorelin<\/strong><\/a> \u2014 GHRH 1-29 analogue \u2014 pituitary endogenous-HGH studies<\/li>\n<li><a href=\"\/ja\/mots-c\/\"><strong>MOTS-c<\/strong><\/a> \u2014 Mitochondrial-derived metabolic peptide \u2014 alternative-mechanism fat-loss studies<\/li>\n<li><a href=\"\/ja\/bac-water\/\"><strong>BAC Water\uff08\u9759\u83cc\u6c34\uff09<\/strong><\/a> \u2014 \u5168\u3066\u306e\u51cd\u7d50\u4e7e\u71e5\u30d0\u30a4\u30a2\u30eb\u306e\u518d\u6eb6\u89e3\u306b\u5fc5\u8981 \u2014 \u7121\u83cc\u30010.9%\u30d9\u30f3\u30b8\u30eb\u30a2\u30eb\u30b3\u30fc\u30eb\u4fdd\u5b58\u5e0c\u91c8\u6db2<\/li>\n<\/ul>","protected":false},"excerpt":{"rendered":"<p>\u2705 \u5b89\u5b9a\u5316hGH 176-191 C\u672b\u7aef\u8102\u80aa\u5206\u89e3\u65ad\u7247\uff08N\u672b\u7aefTyr\u5ef6\u9577\uff09<br \/>\n\u2705 Metabolic Pharmaceuticals Ltd\uff08\u30e2\u30ca\u30b7\u30e5\u5927\u5b66\u30011990\u5e74\u4ee3\u5f8c\u534a\uff09\u306b\u3088\u308b\u958b\u767a<br \/>\n\u2705 GHR\u975e\u4f9d\u5b58\u6027 \u2014 IGF-1\u3001JAK2\/STAT5\u3001\u6210\u9577\u8ef8\u3078\u306e\u95a2\u4e0e\u306a\u3057<br \/>\n\u2705 \u8102\u80aa\u5206\u89e3\uff0b\u8102\u80aa\u5408\u6210\u6291\u5236\u4f5c\u7528\uff1b\u03b23\u30a2\u30c9\u30ec\u30ca\u30ea\u30f3\u53d7\u5bb9\u4f53\u4f9d\u5b58\u7684\uff08\u6a5f\u5e8f\u306f\u5b8c\u5168\u306b\u306f\u89e3\u660e\u3055\u308c\u3066\u3044\u306a\u3044\uff09<br \/>\n\u2705 \u8840\u6f3f\u4e2d\u534a\u6e1b\u671f \u7d044\u5206\uff1b\u7b2cIIb\u76f8\u80a5\u6e80\u75c7\u8a66\u9a13\u306f\u5931\u6557\uff082007\u5e74\uff09\uff1b\u5206\u5b50\u91cf1815.1\u3001CAS 221231-10-3<\/p>\n<p><strong>AOD-9604<\/strong> contains synthetic Tyr-hGH(177-191) peptide.<\/p>","protected":false},"featured_media":71463,"comment_status":"open","ping_status":"closed","template":"","meta":[],"product_brand":[],"product_cat":[5426],"product_tag":[6500,6499,6502,6503,6289,6501,6494],"class_list":["post-71446","product","type-product","status-publish","has-post-thumbnail","product_cat-peptides","product_tag-anti-obesity-drug","product_tag-aod-9604","product_tag-fat-loss-research","product_tag-ghr-decoupled","product_tag-hgh-fragment","product_tag-lipolytic-peptide","product_tag-research-peptide","first","instock","shipping-taxable","purchasable","product-type-variable","has-default-attributes"],"acf":[],"_links":{"self":[{"href":"https:\/\/medsbase.com\/ja\/wp-json\/wp\/v2\/product\/71446","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/medsbase.com\/ja\/wp-json\/wp\/v2\/product"}],"about":[{"href":"https:\/\/medsbase.com\/ja\/wp-json\/wp\/v2\/types\/product"}],"replies":[{"embeddable":true,"href":"https:\/\/medsbase.com\/ja\/wp-json\/wp\/v2\/comments?post=71446"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/medsbase.com\/ja\/wp-json\/wp\/v2\/media\/71463"}],"wp:attachment":[{"href":"https:\/\/medsbase.com\/ja\/wp-json\/wp\/v2\/media?parent=71446"}],"wp:term":[{"taxonomy":"product_brand","embeddable":true,"href":"https:\/\/medsbase.com\/ja\/wp-json\/wp\/v2\/product_brand?post=71446"},{"taxonomy":"product_cat","embeddable":true,"href":"https:\/\/medsbase.com\/ja\/wp-json\/wp\/v2\/product_cat?post=71446"},{"taxonomy":"product_tag","embeddable":true,"href":"https:\/\/medsbase.com\/ja\/wp-json\/wp\/v2\/product_tag?post=71446"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}